Researchers from Berlin’s Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) have gained new insights into how cellular metabolism adapts to periods of starvation to ensure cells get the energy they need to function.
While studying the rare genetic muscular disorder X-linked centronuclear myopathy (XLCNM), the team identified a crucial role for early endosomal lipid signaling in controlling endoplasmic reticulum (ER) morphology and, thereby, mitochondrial form and function to orchestrate the adaptive response of cells to alterations in nutrient supply.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
XLCNM involves a defective gene on the X chromosome, resulting in a developmental disorder of the skeletal muscles. This muscle weakness is so severe that, in many cases, affected children require ventilatory support and are wheelchair-bound. Affected individuals do not survive beyond the age of 10 to 12 years; in severe cases, they die soon after birth.
The genetic defect affects lipid phosphatase MTM1, an enzyme that controls the turnover of a signaling lipid on endosomes, vesicle-like structures in cells involved in the sorting of nutrient receptors. It was during the study of the structure of mutant human muscle cells from patients that the researchers discovered changes in the ER. In healthy cells, the ER forms a large, interconnected network of flattened membrane-enclosed sacs near the nucleus of the cell and narrow tubules in the cell periphery. In diseased cells, this equilibrium is shifted towards the tubules and, moreover, the membrane-enclosed sacs appear perforated. The researchers report in a recent issue of Science that a very similar accumulation of narrow ER tubules and perforated membrane-enclosed sacs occurs in starved cells, in which MTM1 was genetically inactivated.
“Muscles are highly sensitive to starvation; their energy reserves are soon depleted. We therefore began to suspect that the defect in cells from XLCNM patients might be related to an incorrect response to starvation,” says Volker Haucke, director of FMP and coauthor of the study.
When cells are starved, amino acid deficiency occurs. The researchers found that, when this occurs in healthy cells, the ER undergoes changes in shape. The outer narrow tubules regress and are converted into flat membrane-enclosed sacs. This altered structure of the ER enables the energy-supplying mitochondria to fuse together. “Such greatly enlarged ‘giant mitochondria’ are much better able to metabolize fats,” says Dr. Wonyul Jang, lead author of the study.
However, fats cannot be transported or burned efficiently in cells deficient in MTM1. In healthy cells, starvation reduces the contact points between endosomes and the ER, allowing the latter to reshape as a result. In cells of XLCNM patients, however, no contact site reduction occurs. The endosome instead exerts a “pulling force” on the ER, causing the stabilization of peripheral tubules and fenestration of the membrane-enclosed sacs. Since peripheral ER tubules are responsible for mitochondrial fission, mitochondria remain small in the absence of MTM1. In this shape, they are much less able to burn storage fats, resulting in severe energy deficiency in the cell.
“We have found a completely new mechanism for how different compartments in the cell communicate with each other such that cell metabolism adapts in response to food supply,” Haucke adds.
In light of this, the study shows that starvation is extremely harmful to the muscle cells of XLCNM patients, who need constant food intake to prevent muscle proteins from being broken down into amino acids.
In another study published in Proceedings of the National Academy of Sciences, FMP researchers were able to show that defects due to a loss of the lipid phosphatase MTM1 can essentially be repaired by inactivating the “opposing” enzyme, the lipid kinase PI3KC2B. This could potentially work in XLCNM patients. The team, led by Haucke, is currently working to find a suitable inhibitor that can suppress PI3KC2B activity. They have already demonstrated in cell culture that this is possible in principle.